GlassScriptPhysician profile
William Borges Cancel
NPI 1811199904
$12,983.66
in general payments reported to CMS, 2019-2025
19 companies · $901 in 2025
The $901 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,996 · 2020: $2,150 · 2021: $1,482 · 2022: $1,856 · 2023: $2,597 · 2024: $1,001 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,374 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,374.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $5,514.09 | 2019-2024 | Xarelto, Invokana |
| E.R. Squibb & Sons, L.L.C. | $1,391.56 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $1,321.28 | 2022-2025 | Steglatro, Verquvo, Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,037.72 | 2019-2025 | Lifevest |
| Amgen INC. | $894.75 | 2019-2025 | Repatha, Repatha, Evenity |
| Pbg Puerto Rico LLC | $578.56 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $549.64 | 2019-2025 | Lokelma, Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.34 | 2021-2025 | Jardiance |
| Medtronic, INC. | $439.60 | 2022-2025 | Corevalve Evolut R, Micra |
| Boston Scientific Corporation | $311.47 | 2019-2021 | |
| Abbott Laboratories | $158.50 | 2019-2025 | Jot Dx, Mitraclip |
| Verity Pharmaceuticals INC. | $137.81 | 2023 | Vibativ |
| Bayer Puerto Rico INC. | $46.59 | 2025 | Kerendia |
| Novartis Pharmaceuticals Corporation | $44.91 | 2019-2025 | |
| Scpharmaceuticals INC. | $42.86 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $20.00 | 2024 | Arcalyst |
| Pfizer Pharmaceuticals LLC | $20.00 | 2019 | |
| Gilead Sciences, INC. | $13.52 | 2019 | |
| Medtronic Vascular, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Borges Cancel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.